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Staphylococcus aureus bioﬁlms, a leading cause of persistent infections, are highly resistant to immune defenses and antimicrobial
therapies. In the present study, we investigated the contribution of ﬁbrin and staphylokinase (Sak) to bioﬁlm formation. In both
clinical S. aureus isolates and laboratory strains, high Sak-producing strains formed less bioﬁlm than strains that lacked Sak, sug-
gesting that Sak prevents bioﬁlm formation. In addition, Sak induced detachment of mature bioﬁlms. This effect depended on plas-
minogen activation by Sak. Host-derived ﬁbrin, the main substrate cleaved by Sak-activated plasminogen, was a major component of
bioﬁlm matrix, and dissolution of this ﬁbrin scaffold greatly increased susceptibility of bioﬁlms to antibiotics and neutrophil phago-
cytosis. Sak also attenuated bioﬁlm-associated catheter infections in mouse models. In conclusion, our results reveal a novel role for
Sak-induced plasminogen activation that prevents S. aureus bioﬁlm formation and induces detachment of existing bioﬁlms through
proteolytic cleavage of bioﬁlm matrix components.
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Bioﬁlms are involved in the majority of infections and cause an
enormous burden to healthcare systems [1]. One of the leading
pathogens in bioﬁlm-associated infections is Staphylococcus au-
reus [2]. Although this pathogen is a major cause of skin, soft-
tissue, respiratory, bone, joint, and endovascular infections [3],
the staphylococcal bioﬁlm-related infections are among the
most difﬁcult to manage. Bioﬁlms are resistant to antibiotics
and host immune defenses [1, 4, 5], so their treatment is chal-
lenging and costly.
Bioﬁlms are multilayered communities of bacteria proliferat-
ing on surfaces, for example on biomedical implants. First, bac-
teria attach by binding directly to the biomaterial surface or to
host proteins conditioning the surface after implantation. Bio-
ﬁlm growth and maturation form a complex 3-dimensional
structure, with bacterial cells embedded in an extracellular ma-
trix. Finally, some bacteria detach from the mature bioﬁlm lead-
ing to dispersal and spread to new sites of infection [6–9].
Numerous global regulators (agr, sarA, sigB, and sae) are
involved in control of S. aureus bioﬁlm formation and dispersal,
and their exact roles are probably strain speciﬁc [4, 7]. Further-
more, the main bacterial components of the staphylococcal bio-
ﬁlm matrix (either polysaccharides or proteins) are strain
dependent [4, 7]. Much less is known about the role of host-
derived factors in bioﬁlm formation and regulation.
Staphylokinase (Sak) is a plasminogen activator secreted by
the majority of S. aureus strains [10]. It forms complexes with
trace amounts of plasmin present in host plasma. Those com-
plexes subsequently cleave plasminogen to form active plasmin,
a potent broad spectrum protease targeting host proteins, in-
cluding ﬁbrin clots. Plasminogen activation by Sak promotes
bacterial entry and further spread in the skin [11, 12], but it de-
creases the severity of invasive bloodstream infections [13, 14].
The role of Sak in S. aureus bioﬁlm infections has not been stud-
ied, but plasmin could potentially cleave proteins present in the
bioﬁlm matrix. We hypothesize that this activity has a profound
impact on bioﬁlm development in vivo. Indeed, our ﬁndings
suggest that interplay between Sak and host plasminogen and
ﬁbrin plays a crucial role in controlling bioﬁlm formation,
both in vitro and in vivo.
METHODS
Bacterial Strains and Growth Conditions
Congenic S. aureus strains differing in the level of Sak secretion—
LS-1EP, LS-1sak, and LS-1spa-sak—were described elsewhere
[13]. The Newman strain and its congenic coa/vwb mutant
Received 7 March 2015; accepted 22 June 2015; published online 1 July 2015.
Presented in part: International Symposium on Staphylococci & Staphylococcal Infections,
Chicago, Illinois, 26–29 August 2014.
Correspondence: J. Kwiecinski, Department of Rheumatology and Inflammation Research,
University of Gothenburg, Box 480, 405-30 Gothenburg, Sweden (jkwiecinski@gmail.com;
jakub.kwiecinski@rheuma.gu.se).
The Journal of Infectious Diseases® 2016;213:139–48
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society
of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
DOI: 10.1093/infdis/jiv360
Staphylokinase in S. aureus Bioﬁlms • JID 2016:213 (1 January) • 139
lacking both coagulases were described elsewhere [15]. Growth
curves of congenic strains did not differ [13].
We used a collection of S. aureus clinical isolates from inva-
sive infections, described elsewhere [11, 16]. This included 28
isolates from bioﬁlm-associated infections on foreign materials
(line-associated infections and prosthetic joint infections) and
131 isolates from non–bioﬁlm-associated invasive infections,
including soft-tissue infections and bacteremia without focus.
Bacteria were grown with shaking at 37°C in trypticase soy
broth (TSB). For bioﬁlm experiments, if not indicated other-
wise, a mixture of 50% TSB and 50% human plasma was
used, supplemented with 0.5% glucose. In some experiments,
various reagents were added (see Supplementary Methods).
Measurement of Sak
The level of Sak produced by bacteria was measured using a
chromogenic assay [11, 17] in 20-hour-old cultures initiated
by adding equal inoculum of each strain to a fresh broth (all
strains reached stationary phase by the 20-hour time point).
The “high Sak” production in clinical isolates was comparable
to that of LS-1spa-sak.
Bioﬁlm Microplate Assay
A classic microplate method for bioﬁlm measurement was used
[18], with minor modiﬁcations (see Supplementary Methods).
Bioﬁlm Microscopy
Methods for visualization of bioﬁlms and neutrophil-bioﬁlm
interactions in confocal and electron microscopy, along with
details of immunostainings, are described in the Supplementary
Methods.
Primary Adhesion Under Shear Stress
Measurement of bacterial adhesion under ﬂow conditions is de-
scribed in the Supplementary Methods.
Fibrinolytic and Proteolytic Markers
Plasmin activity in bioﬁlm supernatants was measured using
chromogenic assay, as described elsewhere [19]. Fibrin D-di-
mers in supernatants were measured with Asserachrom D-DI
enzyme-linked immunosorbent assay (ELISA; Diagnostica
Stago). Bioﬁlm matrix was extracted [20], and protein concen-
trations were measured with the Bradford assay. Sak protein
concentration was measured with ELISA [12] (details in Sup-
plementary Methods).
Sak Expression in a 7-Day Experiment
To measure Sak expression on different days, we used bioﬁlms
of S. aureus LS-1sak or of 3 randomly chosen clinical isolates
from bioﬁlm-associated infections, secreting similar amounts
of Sak as the LS-1sak. Growth medium was removed daily, bio-
ﬁlms were washed, and fresh medium was added. On selected
days, bioﬁlms were scraped from the bottom of the wells, and
expression of sak mRNA in bioﬁlm and in planktonic cells
was measured by means of reverse-transcription polymerase
chain reaction [11].
Response of Neutrophils to Bioﬁlms
Human neutrophils were separated from buffy coats from
healthy donors by dextran sedimentation and Ficoll-Paque cen-
trifugation [21] and stored on ice until use.
Production of intracellular superoxide was measured by
chemiluminescence in a 96-well plate in a Mithras LB 940 read-
er (Berthold Technologies) [22]. Neutrophils (2 × 105 cells per
well) were added to preformed bioﬁlm in a Krebs-Ringer phos-
phate buffer containing the cell permeable substrate luminol
(10 µg/mL; Sigma) in the presence of the extracellular scaven-
gers superoxide dismutase (50 U/mL, Worthington Biochemi-
cal Corporation) and catalase (2000 U/mL; Worthington).
Determination of Minimum Inhibitory Concentration for Antibiotic
The minimum inhibitory concentration (MIC) of vancomycin
against planktonic bacteria was measured with a microdilution
assay according to the ISO 20 776 standard, and the MIC
against bioﬁlms was determined with a thiazolyl blue tetrazoli-
um bromide (MTT) chromogenic assay to detect bioﬁlm viabil-
ity [23]. Duplicate determinations were performed.
Animals
C57BL/6 mice (Charles River) aged 6–9 weeks were used, of
both sexes (subcutaneous catheter infections) or male ( jugular
vein catheter infections). All experiments were approved by the
Animal Research Ethical Committee of Gothenburg and the
Ethical Committee of the University of Leuven.
Subcutaneous Catheter Bioﬁlm Model
Catheter segments (1.5 cm) (BD Venﬂon; 16 gauge; Becton
Dickinson) were coated overnight with 20% mouse plasma,
washed, ﬁlled with 10 µL of 1% overnight bacterial suspension
in TSB with 0.5% glucose and 0.05 mg/mL human plasminogen
(or phosphate-buffered saline [PBS]), and implanted subcuta-
neously on the back of mice. An implant infected with S. aureus
strain LS-1EP was inserted on one ﬂank, and an implant with
LS-1spa-sak on the other. To provide human plasminogen,
50 µL of 200 µg/mL plasminogen (or PBS) was injected daily
into the lumen of the catheter. On day 3 after implantation,
catheters were excised, rinsed, placed in 1 mL of PBS, and son-
icated for 5 minutes to dislodge attached bioﬁlm, and colony-
forming units were then counted.
Jugular Vein Catheter Bioﬁlm Model
The intravascular jugular vein catheter model was performed as
described elsewhere [24], with minor modiﬁcations (described
in Supplementary Methods, along with details of adenovirus-
mediated human plasminogen expression in mice).
Statistical Analysis
Statistical calculations were done with Prism software, version
6.03 (GraphPad Software) and differences were considered sig-
niﬁcant at P < .05 (2 tailed). Test details are described in the
Supplementary Methods.
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RESULTS
Secretion of Sak in S. aureus Isolates From Bioﬁlm Infections
Clinical S. aureus invasive infection isolates produced varying
levels of Sak, ranging from undetectable (no optical density
increase in the chromogenic assay) to very high levels (optical
density increase of >1). Strikingly, none of the isolates from
bioﬁlm-associated infections secreted high levels of Sak
(Figure 1A and 1B). To examine whether there is a negative
association between high Sak production and S. aureus bio-
ﬁlm, we measured bioﬁlm formation by selected strains in
broth supplemented with 50% human plasma. High Sak-
secreting clinical strains formed signiﬁcantly less bioﬁlm
than Sak-negative strains (Figure 1C). This suggests that a
high level of Sak is not compatible with bioﬁlm formation
when host plasma is present.
Effect of Sak on Bioﬁlm Formation and Dispersal in Plasma
We used a panel of congenic S. aureus strains differing in the
Sak secretion level [13]. Strain LS-1EP does not secrete Sak,
LS-1sak secretes Sak moderately, and LS-1spa-sak has high
Sak secretion (comparable to the high-secreting clinical iso-
lates). In the bioﬁlm assay incorporating plasma, striking differ-
ences were seen between the strains (Figure 2A). LS-1EP formed
dense bioﬁlm, which grew further between 24 hours and 48
hours of incubation. In contrast, LS-1spasak was unable to
form bioﬁlm. For LS-1sak strain, bioﬁlm formed at 24 hours
was similar to that produced by the Sak-negative control strain.
However, the bioﬁlm partially disintegrated after 48 hours, and
the bioﬁlm mass was signiﬁcantly lower than at 24 hours. Viable
bacteria counts in bioﬁlm followed the same pattern (Figure 2B).
Differences between strains disappeared when pure TSB with-
out host plasma was used (Figure 5D).
Confocal microscopy of the bioﬁlms conﬁrmed that both LS-
1EP and LS-1sak initially formed thick, 3-dimensional bioﬁlm
structures, whereas LS-1spa-sak formed only small clusters of
cells and even after 48 hours was unable to form a complete bi-
oﬁlm (Figure 2C). Bioﬁlms of LS-1sak disintegrated after 48
hours, but LS-1EP bioﬁlm retained its thick structure. The
same pattern was observed with scanning electron microscopy
(Figure 2D). Thick bioﬁlms of LS-1EP covered the entire surface
and were composed of cell clusters embedded in an extracellular
matrix. Bioﬁlms of LS-1sak had a similar appearance after 24
hours, although after 48 hours they appeared thinner and less
compact, and in many places the underlying surface became ex-
posed. With LS-1spa-sak, barely any matrix was visible, with
only a few “unembedded” bacteria attached to the surface.
When initial adhesion to plasma-coated surface was investi-
gated under physiological shear stress, the LS-1spa-sak failed to
adhere, whereas LS-1EP did adhere (Figure 3A), showing that
Sak not only prevented accumulation but also inhibited initial
adhesion to the surface—the ﬁrst step of bioﬁlm formation.
The addition of recombinant Sak to an established bioﬁlm
formed by LS-1EP caused detachment of bioﬁlm (Figure 3B),
showing directly that Sak causes disintegration and dispersal
of bioﬁlm. Overall, the in vitro experiments showed that a
high level of Sak inhibited bioﬁlm formation in the presence
of plasma. The moderate production of Sak by S. aureus did
not interfere with initial bioﬁlm formation but promoted sub-
sequent detachment of already formed bioﬁlms.
To investigate the expression of the sak gene, sakmRNA levels
were measured in cells from bioﬁlms grown in microwells for up
to 7 days. A characteristic pattern was observed in both LS-1sak
(Supplementary Figure 1A) and 3 clinical isolates from bioﬁlm-
associated infections (Supplementary Figure 1B). The expression
of Sak by cells within the bioﬁlmwas low and decreased over time.
In contrast, the expression of Sak by planktonic cells was higher
and markedly increased with time. This suggests that Sak expres-
sion might be associated with planktonic bacteria detaching from
the existing bioﬁlm rather than with bacteria persisting inside the
bioﬁlm and/or that Sak expression is radically decreased inside
bioﬁlms. Such a hypothesis is strengthened by a direct ELISA
measurement, showing reduced levels of Sak protein secreted
from bioﬁlms, compared with planktonic cultures (Supplementa-
ry Figure 1C), in line with observations published elsewhere [25].
Mediation of Sak Effect by Plasminogen Activation
A plausible mechanism for the observed effects is the activation
of host plasminogen by Sak into plasmin and subsequent
Figure 1. High staphylokinase (Sak) production inhibits biofilm formation in clinical Staphylococcus aureus isolates. A, B, Levels of Sak secretion by clinical isolates from
biofilm-associated infections (n = 28) and non–biofilm-associated invasive infections (n = 131). C, Biofilm formation in vitro in medium supplemented with human plasma by
clinical isolates with high Sak secretion and by randomly chosen isolates with no Sak secretion (n = 19). Horizontal bar represents median. Abbreviation: ΔOD405, change in
optical density at 405 nm.
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cleavage of ﬁbrin and other bioﬁlm proteins. To test this hypoth-
esis, we measured the plasmin activity in bioﬁlm supernatants
was measured and found that it correlated inversely with bioﬁlm
formation and Sak secretion (Figure 4A). The level of the D-
dimer (a ﬁbrinolysis marker) was also higher in supernatants of
strains producing Sak (Supplementary Figure 2A). Furthermore,
the overall protein content of the bioﬁlms negatively correlated
with the plasmin activity (Supplementary Figure 2B).
Blockade of either plasmin activity by aprotinin- or Sak-
induced plasminogen activation by tranexamic acid restored
Figure 2. Staphylokinase (Sak) modulates biofilm formation and detachment by S. aureus. Biofilm formation by congenic S. aureus strains differing in the level of secreted
Sak (EP, no secretion; sak, moderate secretion; spa-sak, high secretion) assessed in medium supplemented with human plasma after 24 and 48 hours. A, Biofilm mass (n = 9).
B, Colony-forming unit (CFU) counts (n = 7–10). C, Three-dimensional appearance with confocal microscopy (diameter, 160 × 160 × 65 µm). D, Scanning electron microscopy
(image width, 23 µm). Means and standard errors of the mean are shown. Abbreviation: OD570, optical density at 570 nm.
Figure 3. Staphylokinase (Sak) affects different phases of Staphylococcus aureus biofilm development. A, Effect of high Sak secretion on primary adhesion under shear
stress in flow system (n = 7). B, Detachment of biofilm mass after addition of exogenous Sak (5 µg/mL) (n = 6). Means and standard errors of the mean are shown. Abbreviations:
OD570, optical density at 570 nm; PBS, phosphate-buffered saline.
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bioﬁlm formation by LS-1spa-sak to the control level (Figure 4B
and Supplementary Figure 2C). Depletion of plasminogen from
plasma also restored normal bioﬁlm formation in LS-1spa-sak
(Figure 4C). Sak is active only toward plasminogen from
human and certain animals (Supplementary Figure 2D); there-
fore, LS-1spa-sak formed bioﬁlms only when bacteria grew in
the presence of plasma from animal species where Sak was
unable to activate plasminogen (Figure 4D). Adding active
plasmin to medium inhibited bioﬁlm development in a dose-
dependent fashion (Figure 4E), conﬁrming plasminogen activa-
tion as the mechanism of observed differences.
Fibrin as a Scaffold for the Bioﬁlm Matrix
Because ﬁbrin is the main target of active plasmin and bioﬁlm
formation was negligible in ﬁbrinogen-depleted plasma (Fig-
ure 4C), our data point to a crucial role for ﬁbrin in bioﬁlm for-
mation. On examination of the bioﬁlm structure, it seemed that
S. aureus, when grown in the presence of plasma, uses host pro-
teins to construct the bioﬁlm matrix. Immunostaining revealed
that, in addition to bacterial cells, bioﬁlms incorporated human
serum proteins, including ﬁbrin(ogen) (Supplementary Fig-
ure 3A). Fibrin clumps were present in the bioﬁlm matrix and
were a part of the bioﬁlm’s scaffold. They were also present on
the bacterial surface, tethering individual cells to the bioﬁlm ﬁ-
brin matrix (Figure 5A). This suggests an important structural
role for ﬁbrin within staphylococcal bioﬁlms, especially because
S. aureus secretes its own coagulases inducing ﬁbrin deposition
[26]. Indeed, bioﬁlm formation was inhibited and the ﬁbrin
scaffold surrounding bacteria disappeared with the addition of
a direct thrombin inhibitor (dabigatran), which also inhibits S.
aureus–induced ﬁbrin formation [26]. No bioﬁlm was formed
when S. aureus mutant lacking coagulases was used or when
the experiment was performed in pure medium without host
plasma (Figure 5B).
Pure broth was supplemented with components needed for
coagulation and ﬁbrinolysis, that is, prothrombin (to be activat-
ed by staphylococcal coagulases and mediate ﬁbrin deposition),
ﬁbrinogen (to form a ﬁbrin mesh in the bioﬁlm matrix), and
plasminogen (to lyse ﬁbrin after its SAK-mediated activation).
Under these conditions, the same pattern of bioﬁlm formation
by LS-1EP, LS-1sak and LS-1spa-sak was seen as in broth with
plasma (Figure 5C). No difference between the strains was vis-
ible in unsupplemented broth (Figure 5D). In accordance with
the proposed model, omission of plasminogen from the broth
Figure 4. Staphylokinase (Sak) mediates its effect on Staphylococcus aureus biofilm by activating plasminogen. A, Plasmin activity in the supernatants of biofilm cultures of
S. aureus strains differing in Sak secretion (n = 9). B, Effect of plasmin inhibitors tranexamic acid (TXA) and aprotinin (apr) on biofilm formation by strain secreting no Sak or high
level of Sak (n = 6–9). C, Biofilm formation by strain secreting no Sak or high level of Sak in human plasma depleted of plasminogen (plg) or fibrinogen (fg) (n = 3). D, Biofilm
formation by strain secreting no or high level of Sak in plasma from various animal species, where Sak is either active or unable to activate plasminogen (n = 5). E, Effect of
plasmin addition on biofilm formation by strain LS1EP (n = 3). Means and standard errors of the mean are shown. Abbreviations: A405, absorbance at 405 nm; OD570, optical
density at 570 nm.
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completely inhibited bioﬁlm dispersal and allowed all 3 strains
to form a thick, ﬁbrin-rich matrix (Figure 5E ).
Effect of Sak on Bioﬁlm Susceptibility to Antibiotics and Host Defenses
When neutrophils engulf a microbe, there is a robust produc-
tion of reactive oxygen species (ROS) within the phagosome
of these cells [27, 28]. Intracellular ROS production from neu-
trophils was very weak on interaction with bioﬁlms formed by
LS-1EP or LS-1sak. In contrast, neutrophils interacting with the
bacterial clumps formed by the LS-1spa-sak strain rapidly re-
sponded with high-level ROS production (Figure 6A). This dif-
ference was not due to direct effects of Sak on neutrophils,
Figure 5. Fibrin is an essential component of biofilm matrix and is destroyed by staphylokinase (Sak)–induced fibrinolysis. A, Section of Staphylococcus aureus LS-1EP biofilm in
transmission electron microscopy, stained with 10 nm immunogold technique (black dots) against fibrin(ogen). Upper panel shows even distribution of bacteria in the matrix containing
flocculent material and irregular strands. The “darkest” lines are sectioning artifacts. Middle panels show magnified insets from the upper row. Left panel shows positive staining of
fibrin on bacterial surface. Central and rightmost bacterial cells were “topped” by tangential sectioning, thus including more cell surface in section and showing more intensive
staining than cells sectioned equatorially. Right panel shows intensive labeling of a dense structure in the matrix, identifying it as a fibrin mesh. Lower panels show various patterns
of immunostaining. Staining on the staphylococcal surface (arrowheads) is shown in the left panels. Staining of filamentous material radiating from bacterial surface (arrows), linking
individual staphylococci to the intracellular fibrin scaffold in matrix are shown in the right panels (scale bars, 2 and 0.5 µm). No staining was seen in isotype controls (not shown).
B, Scanning electron microscopy images of S. aureus Newman biofilms formed in medium with plasma in different conditions: control, with dabigatran (coagulation inhibitor) added,
with congenic S. aureus coa/vwb mutant lacking both coagulases or when no plasma was present (×3000 magnification). C, Effect of Sak on biofilm formation in trypticase soy broth
(TSB) supplemented with plasminogen (plg), fibrinogen (fg), and prothrombin (pth) (n = 9). D, No effect of Sak on biofilm formation in pure TSB, n = 6–9. Means and standard errors of
the mean are shown. E, Scanning electron microscopic images of biofilms of congenic S. aureus strains differing in the level of secreted Sak in TSB supplemented with fibrinogen and
prothrombin, with or without plasminogen added (×3000 magnification). Abbreviation: OD570, optical density at 570 nm.
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because Sak alone had no impact on ROS production (data not
shown). Moreover, no difference in ROS production was found
among the strains when bioﬁlms were grown in broth without
plasma (Figure 6B). This indicates that the thick bioﬁlm matrix
of ﬁbrin and host proteins protects LS-1EP and LS-1sak from im-
mune recognition and attack, whereas the bioﬁlm residues formed
by LS-1spa-sak, lacking the shielding matrix of host proteins, are
exposed to neutrophil phagocytosis. This was also conﬁrmed by
microscopic observation: many neutrophils phagocytosing bacte-
rial clumps were seen in LS-1spa-sak samples compared with LS-
1EP and LS-1sak (Supplementary Figure 4).
When ﬂuorescently labeled neutrophils and staphylococci in
bioﬁlm were visualized with confocal microscopy, the same pat-
tern emerged. Neutrophils attached to and penetrated into the
clumps of LS-1spa-sak; many of them contained ingested bac-
teria. In contrast, neutrophils failed to enter into the LS-1EP
and LS-1sak bioﬁlms and remained on the top of the bioﬁlm
matrix. Despite their proximity to bacteria, very few neutrophils
contained phagocytosed staphylococci (Figure 6C).
All 3 strains exhibited the same vancomycin susceptibility
when tested as planktonic cells (MIC, 0.5 mg/L). In the case
of bioﬁlm-embedded bacteria LS-1EP and LS-1sak, resistance
increased dramatically, and even >4000 times higher concentra-
tions of vancomycin failed to kill bacteria (MIC, >2048 mg/L).
This was in sharp contrast to LS-1spa-sak, where the adherent
clumps of cells had only a slightly elevated vancomycin MIC
(8 mg/L) (Figure 6D). Overall, the bioﬁlm matrix was essential
both for antibiotic resistance and for immune evasion. Dissolu-
tion of this matrix induced by Sak rendered bacteria vulnerable.
Effect of Sak on Bioﬁlm Formation in Mouse Infection Models
Both the in vitro data and the observations with clinical isolates
strongly suggested an inhibitory effect of high Sak secretion on
bioﬁlm formation. To conﬁrm this in vivo, we used mouse sub-
cutaneous and intravascular catheter infection models. Because
Sak is speciﬁc for human plasminogen and has very low activity
toward murine plasminogen (Supplementary Figure 2D), we
provided human plasminogen either locally, by injection into
the catheter lumen, or systemically, using an adenoviral vector
system that expressed human plasminogen in mice.
In subcutaneous catheters inoculated with staphylococci, in-
jections of human plasminogen resulted in signiﬁcantly smaller
Figure 6. Staphylokinase (Sak) reduces the resistance of biofilm resistance to immune system and antibiotics. A, Intracellular reactive oxygen species (ROS) production in
neutrophils encountering biofilms of the congenic strains differing in Sak secretion grown in presence of human plasma or B, in pure trypticase soy broth (TSB) medium (n = 3).
C, Representative images of neutrophils interacting with biofilms differing in Sak secretion, including vertical (upper panel) and horizontal (middle panel) sections through
biofilm obtained from confocal imaging (scale bar, 50 µm) and: magnification of neutrophils next to biofilm pieces (scale bar, 5 µm) (lower panel). D, Minimum inhibitory
concentration (MIC) of vancomycin against Staphylococcus aureus strains in planktonic form or in biofilm. Abbreviation: AU, arbitrary units.
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levels of LS-1spa-sak attached to the biomaterial compared with
LS-1EP (Figure 7A). In contrast, no such effect occurred in con-
trol animals injected with saline, which indicates that the inhib-
itory effect of Sak on catheter infection was due to interaction of
Sak and human plasminogen.
The same pattern was observed in the model of intravascular
jugular vein catheter infection in mice expressing human plas-
minogen from an adenoviral vector. In the LS-1EP–infected an-
imals, bioﬁlms developed on all catheters (7/7), compared with
2 of 6 catheters in the LS-1spa-sak–infected mice (Figure 7B).
Furthermore, signiﬁcantly fewer LS-1spa-sak cells were found
on implanted catheters compared with strain LS-1EP (Fig-
ure 7C). This effect did not occur in control mice without ex-
pression of human plasminogen, conﬁrming that the capacity of
Sak to activate plasminogen is essential for reducing S. aureus
intravascular catheter infection.
DISCUSSION
Our study demonstrates that Sak controls development of S. au-
reus bioﬁlm by activating plasmin(ogen)-dependent proteolysis
and ﬁbrinolysis, which in turn prevents bacterial adhesion to
surfaces and destroys bioﬁlm matrices composed of ﬁbrin, lead-
ing to breakdown of the bioﬁlm architecture and bacterial
detachment.
Host proteins deposited on implant surfaces mediate the pri-
mary adhesion of staphylococci [2, 7]. Bacteria-induced ﬁbrin
formation plays a role in this attachment [24], but as we
noted, the importance of ﬁbrin is not limited to the attachment
phase. Abundant ﬁbrin(ogen) was found incorporated into the
bioﬁlm matrix, conﬁrming other observations of structures re-
sembling ﬁbrin meshes inside bioﬁlms [24, 29–31]. Electron mi-
croscopy showed a ﬁbrin scaffold inside the bioﬁlm matrix, with
individual bacteria attached to it. Fibrin molecules on the S. au-
reus cell surface cross-linked bacteria with the interstitial depos-
ited ﬁbrin, which is likely to be mediated by S. aureus ﬁbrin
(ogen)-binding surface proteins [32].Bioﬁlms formed in clinical
situations are therefore most likely composed not only of bacte-
ria-derived but also of host-derived constituents. Unlike bacte-
ria-derived matrix components, proteins and polysaccharides,
present in some strains only [4, 6, 7], those host-derived constit-
uents are present in vivo in bioﬁlms of all strains. Interestingly,
this bioﬁlm matrix protects bacteria from neutrophil phagocy-
tosis, because neutrophils were unable to penetrate into the bio-
ﬁlm. The presence of host proteins such as ﬁbrin in this matrix
hampered the immune recognition of the pathogen. This is in
line with other reports suggesting inhibition of leukocyte activa-
tion and bacterial killing by ﬁbrin [33, 34]. Therefore, both the
inhibition of ﬁbrin formation and the ﬁbrinolysis induced by
Sak enhance the clearance of S. aureus by neutrophils.
Production of high Sak levels, as observed with the LS-1spa-
sak strain and a subset of clinical isolates, blocks bacterial at-
tachment and subsequent bioﬁlm formation by activating
local ﬁbrinolysis and proteolysis. Even if some cells manage to
attach to the surface, the absence of a ﬁbrin scaffold prevents
successful bioﬁlm formation. Without the ﬁbrin-rich matrix,
bacteria remain vulnerable to attack by phagocytes and
antibiotics.
In contrast to the strains secreting high amount of Sak, the
strains with lower Sak levels managed to adhere and form a bio-
ﬁlm matrix. Expression of Sak within those bioﬁlms was re-
duced in comparison with planktonic cells. Under these
circumstances, Sak might play a role in bioﬁlm dispersal during
the detachment phase. Bioﬁlm dispersal happens as bioﬁlms
mature and can be mediated by phenol-soluble modulins, bac-
terial proteases, and nucleases [6, 7, 35–38]. Because ﬁbrin scaf-
fold forms a signiﬁcant part of bioﬁlm matrix, cleavage of ﬁbrin
matrix might be necessary for successful bacterial detachment.
Indeed, addition of exogenous Sak to a preformed bioﬁlm in-
duced detachment. It is noteworthy that Sak, proteases, and
phenol-soluble modulins are all regulated by the agr quorum-
Figure 7. High staphylokinase (Sak) secretion inhibits biofilm formation in mouse catheter infection models. A, Colony-forming units (CFUs) in biofilms formed by Staph-
ylococcus aureus strains either producing no (LS-1EP) or high amounts of Sak (LS-1spa-sak) within subcutaneous catheters. The implanted catheters were injected into the
lumen by either human plasminogen (h-plg; n = 8) or buffer (n = 7). Lines connect paired samples from a single mouse. B, The percentage of infected catheters. C, CFUs in
biofilms formed in catheters implanted in the jugular vein after inoculation with the S. aureus LS-1EP or LS-1spa-sak in mice treated with an adenovirus gene therapy vector
expressing human plasminogen (n = 6–7) or in control mice treated with vector carrying a sham irrelevant sequence (n = 5–6). Median value (horizontal line), area between 25th
and 75th percentiles (box), and minimal and maximal values (whiskers) are shown. Abbreviation: NS, not significant.
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sensing system [35, 37], so they are likely to be coexpressed and
form a powerful, synergistic mechanism of bioﬁlm detachment.
Our observation of LS-1EP and LS-1sak bioﬁlms interacting
with immune cells and antibiotics demonstrated that at early
time points (at 24 hours, when assays were performed), before
Sak-induced dispersal occurs, bioﬁlms of Sak-moderate strains
would be as protected as those of Sak-deﬁcient strains.
S. aureus captures plasminogen directly on its surface
through numerous receptors [39–42] and either activates it
through Sak secretion or relies on host plasminogen activators.
The latter method, however, is less efﬁcient than the pro-
nounced Sak-induced activation, and probably has a negligible
role in control of bioﬁlm structuring and dispersal, because no
induction of plasmin activity was observed in supernatants of
Sak-deﬁcient bioﬁlms. This suggests that Sak is the main regu-
lator of ﬁbrinolysis in bioﬁlms.
In summary, our study demonstrates the importance of host-
derived factors in S. aureus bioﬁlm formation and draws atten-
tion to the central role of Sak in regulation of different phases of
bioﬁlm development (Supplementary Figure 5). By inducing
cleavage of host-derived ﬁbrin, Sak prevents bacterial attach-
ment to surfaces and the subsequent formation of a bioﬁlm ma-
trix, whereas in mature bioﬁlms it induces detachment of
bacteria by degrading the ﬁbrin scaffold holding bioﬁlms to-
gether. Staphylococci exploit both host coagulation and ﬁbrino-
lysis, manipulating them to control the bioﬁlm formation and
dispersal. Importantly, many other bacterial species can induce
ﬁbrinolysis in a similar fashion to S. aureus, either by secreting a
plasminogen activator or by attracting host plasmin to their sur-
faces [43]. Therefore, the mechanism described in our study is
relevant to other pathogens, and ﬁbrinolysis might become a
universal target for antibioﬁlm therapies.
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